DelveInsight’s “B-cell Non-Hodgkin Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the B-cell Non-Hodgkin Lymphoma, historical and forecasted epidemiology as well as the B-cell Non-Hodgkin Lymphoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the B-cell Non-Hodgkin Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; B-cell Non-Hodgkin Lymphoma Market Forecast
Some of the key facts of the B-cell Non-Hodgkin Lymphoma Market Report:
- The B-cell Non-Hodgkin Lymphoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
- As per SEER, 2020, estimated that there would be near to 77,240 new cases of Non-Hodgkin Lymphoma in 2020 in the United States
- In August 2021, Together, HUTCHMED Limited and Epizyme, Inc. will conduct research, develop, produce, and market TAZVERIK in Greater China, which includes Taiwan, Hong Kong, Macau, and mainland China
- An antibody-drug conjugate (ADC) called naratuximab emtansine (Debio 1562) that targets CD37 is a potential new treatment for people with B-cell malignancies such non-Hodgkin’s lymphomas (NHL)
- Key B-cell Non-Hodgkin Lymphoma Companies: Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics, and others
- Key B-cell Non-Hodgkin Lymphoma Therapies: Capivasertib, ME 401, Odronextamab, Tazemetostat, SHR145, Rituximab (RTX), Blinatumomab, lipegfilgrastim, SyB L-0501, Ibrutinib, and others
- The B-cell Non-Hodgkin Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage B-cell Non-Hodgkin Lymphoma pipeline products will significantly revolutionize the B-cell Non-Hodgkin Lymphoma market dynamics.
B-cell Non-Hodgkin Lymphoma Overview
NHL represents a heterogeneous group of malignancies of different biology and prognosis and can be divided into aggressive (fast-growing), intermediate, or indolent (slow-growing), and can develop from either B-cells or T-cells. Lymphomas that occur after allogeneic bone marrow or stem cell transplantation are usually B-cell non-Hodgkin lymphomas.
Get a Free sample for the B-cell Non-Hodgkin Lymphoma Market Report –
https://www.delveinsight.com/sample-request/b-cell-non-hodgkin-lymphoma-market
B-cell Non-Hodgkin Lymphoma Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
B-cell Non-Hodgkin Lymphoma Epidemiology Segmentation:
The B-cell Non-Hodgkin Lymphoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Prevalence of B-cell Non-Hodgkin Lymphoma
- Prevalent Cases of B-cell Non-Hodgkin Lymphoma by severity
- Gender-specific Prevalence of B-cell Non-Hodgkin Lymphoma
- Diagnosed Cases of Episodic and Chronic B-cell Non-Hodgkin Lymphoma
Download the report to understand which factors are driving B-cell Non-Hodgkin Lymphoma epidemiology trends @ B-cell Non-Hodgkin Lymphoma Epidemiology Forecast
B-cell Non-Hodgkin Lymphoma Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the B-cell Non-Hodgkin Lymphoma market or expected to get launched during the study period. The analysis covers B-cell Non-Hodgkin Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the B-cell Non-Hodgkin Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
B-cell Non-Hodgkin Lymphoma Therapies and Key Companies
- Capivasertib: AstraZeneca
- ME 401: Hrain Biotechnology Co., Ltd.
- Odronextamab: Regeneron Pharmaceuticals
- Tazemetostat: Eisai Co., Ltd.
- SHR145: Jiangsu HengRui Medicine Co.
- Rituximab (RTX): MorphoSys AG
- Blinatumomab: Amgen
- lipegfilgrastim: Teva Branded Pharmaceutical
- SyB L-0501: SymBio Pharmaceuticals
- Ibrutinib: Janssen Pharmaceuticals
Discover more about therapies set to grab major B-cell Non-Hodgkin Lymphoma market share @ B-cell Non-Hodgkin Lymphoma Treatment Market
Scope of the B-cell Non-Hodgkin Lymphoma Market Report
- Study Period: 2019–2032
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key B-cell Non-Hodgkin Lymphoma Companies: Roche, Eli Lilly, Janssen, Corvus Pharmaceuticals, Rafael Pharmaceuticals, AbbVie, ADC Therapeutics, Genetech, Tessa Therapeutics, Bristol Myers Squibb, Nanjing Yoko Biomedical, Nektar Therapeutics, Loxo Oncology, Debiopharm, CarsGen Therapeutics, Angiocrine Bioscience, Bio-thera solutions, HUTCHMED, Epizyme, MEI Pharma, Mustang Bio, Autous, Scopus Biopharma, Allogene Therapeutics, TG Therapeutics, AI therapeutics, and others
- Key B-cell Non-Hodgkin Lymphoma Therapies: Capivasertib, ME 401, Odronextamab, Tazemetostat, SHR145, Rituximab (RTX), Blinatumomab, lipegfilgrastim, SyB L-0501, Ibrutinib, and others
- B-cell Non-Hodgkin Lymphoma Therapeutic Assessment: B-cell Non-Hodgkin Lymphoma current marketed and B-cell Non-Hodgkin Lymphoma emerging therapies
- B-cell Non-Hodgkin Lymphoma Market Dynamics: B-cell Non-Hodgkin Lymphoma market drivers and B-cell Non-Hodgkin Lymphoma market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- B-cell Non-Hodgkin Lymphoma Unmet Needs, KOL’s views, Analyst’s views, B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement
To know more about B-cell Non-Hodgkin Lymphoma companies working in the treatment market, visit @ B-cell Non-Hodgkin Lymphoma Clinical Trials and Therapeutic Assessment
Table of Contents
1. B-cell Non-Hodgkin Lymphoma Market Report Introduction
2. Executive Summary for B-cell Non-Hodgkin Lymphoma
3. SWOT analysis of B-cell Non-Hodgkin Lymphoma
4. B-cell Non-Hodgkin Lymphoma Patient Share (%) Overview at a Glance
5. B-cell Non-Hodgkin Lymphoma Market Overview at a Glance
6. B-cell Non-Hodgkin Lymphoma Disease Background and Overview
7. B-cell Non-Hodgkin Lymphoma Epidemiology and Patient Population
8. Country-Specific Patient Population of B-cell Non-Hodgkin Lymphoma
9. B-cell Non-Hodgkin Lymphoma Current Treatment and Medical Practices
10. B-cell Non-Hodgkin Lymphoma Unmet Needs
11. B-cell Non-Hodgkin Lymphoma Emerging Therapies
12. B-cell Non-Hodgkin Lymphoma Market Outlook
13. Country-Wise B-cell Non-Hodgkin Lymphoma Market Analysis (2019–2032)
14. B-cell Non-Hodgkin Lymphoma Market Access and Reimbursement of Therapies
15. B-cell Non-Hodgkin Lymphoma Market Drivers
16. B-cell Non-Hodgkin Lymphoma Market Barriers
17. B-cell Non-Hodgkin Lymphoma Appendix
18. B-cell Non-Hodgkin Lymphoma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services